D'Addessi A, Racioppi M, Giustacchini M, Alcini A, Alcini E
Università Cattolica del Sacro Cuore, Roma Cattedra di Urologia.
Minerva Urol Nefrol. 1995 Sep;47(3):105-11.
In this study the authors present their experience of treatment of intraglandular prostate cancer with 125I seed implantation. At ten years, the overall survival for T1 and T2 stages is 71% and 57% respectively; and for G1, G2 and G3 grades the survival rate is 84%, 54% and 44% respectively; NED ten-year survival is 53% and 52% for T1 and T2 stages, 84%, 40% and 33% for G1, G2, and G3 grades respectively. The statistical evaluation seems to confirm that iodine brachytherapy is suitable for well differentiated and small volume tumors. Local recurrences, complications and side effects are also reported and compared to corresponding data collected following external radiotherapy and radical prostatectomy; the survival results are similar, but the incidence of complications is lower following implantation and in particular regarding continence and potency. In conclusion, the authors believe that iodine seed implantation could offer patients, who are often young and asymptomatic, satisfactory chances of survival and a very high quality of life.
在本研究中，作者介绍了他们使用125I粒子植入治疗前列腺腺内癌的经验。十年时，T1和T2期的总生存率分别为71%和57%；G1、G2和G3级的生存率分别为84%、54%和44%；T1和T2期无疾病证据（NED）的十年生存率分别为53%和52%，G1、G2和G3级分别为84%、40%和33%。统计评估似乎证实碘近距离放射治疗适用于高分化和小体积肿瘤。还报告了局部复发、并发症和副作用，并与外照射放疗和根治性前列腺切除术后收集的相应数据进行了比较；生存结果相似，但植入后并发症的发生率较低，尤其是在控尿和性功能方面。总之，作者认为碘粒子植入可为通常年轻且无症状的患者提供满意的生存机会和非常高的生活质量。
